Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
LogicBio Therapeutics, Inc. (LOGC)
|
Add to portfolio |
|
|
|
| Price: |
$6.40
| | Metrics |
| OS: |
33.0
|
M
| |
-149
|
% ROE
|
| Market cap: |
$211
|
M
| |
|
|
|
Net cash:
|
$32.1
|
M
| |
$0.97
|
per share
|
|
EV:
|
$179
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($29.4)
|
M
| |
|
|
|
EBIT
|
($30.1)
|
M
| |
|
|
| EPS |
($0.95)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 5.4 | 3.5 | 0.0 | 0.0 | 0.0 | 2.0 |
| Revenue growth | 56.6% | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 |
| Gross profit | 5.4 | 3.5 | 0.0 | 0.0 | 0.0 | -1.4 |
| Gross margin | 100.0% | 100.0% | | | | -67.6% |
| Research and development | 28.2 | 22.8 | 30.7 | 11.1 | 3.6 | |
| General and administrative | 16.2 | 12.2 | 10.4 | 6.9 | 2.3 | 1.4 |
| EBIT | -39.0 | -31.5 | -41.0 | -17.9 | -5.9 | -3.4 |
| EBIT margin | -720.6% | -912.3% | | | | -167.6% |
| Pre-tax income | -40.1 | -32.4 | -40.1 | -17.5 | -5.7 | -3.4 |
| Income taxes | 0.0 | 0.2 | 0.0 | 0.1 | 0.1 | 0.0 |
| Tax rate | 0.1% | | | | | |
| Net income | -40.0 | -32.6 | -40.1 | -17.6 | -5.8 | -3.4 |
| Net margin | -739.9% | -944.4% | | | | -168.9% |
| |
| Diluted EPS | ($1.24) | ($1.29) | ($1.78) | ($3.04) | ($4.15) | ($4,037.40) |
| Shares outstanding (diluted) | 32.4 | 25.4 | 22.6 | 5.8 | 1.4 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|